Open AccessMedicineBiology

G. Mjaess, A. Karam, F. Aoun, S. Albisinni, T. Roumeguère

2020.5.22PROGRES EN UROLOGIE

DOI: 10.1016/j.purol.2020.05.007

tlooto Summary

The pathophysiology of this sex-discrepancy is described, based on the infectivity mechanism of the coronavirus including the Angiotensin-Converting Enzyme 2, the Type II transmembrane Serine Protease, and the androgen receptor to help understand the susceptibility of urological patients, especially those receiving androgen deprivation therapy for prostate cancer, and testosterone replacement therapy.

Abstract

COVID-19 is the pandemic that hit the world starting December 2019. Recent studies and international statistics have shown an increased prevalence, morbidity as well as mortality of this disease in male patients compared to female patients. The aim of this brief communication is to describe the pathophysiology of this sex-discrepancy, based on the infectivity mechanism of the coronavirus including the Angiotensin-Converting Enzyme 2 (ACE2), the Type II transmembrane Serine Protease (TMPRSS2), and the androgen receptor. This could help understand the susceptibility of urological patients, especially those receiving androgen deprivation therapy for prostate cancer, and testosterone replacement therapy.

Citation format

MJAESS, G., et al. COVID-19 and the male susceptibility: The role of ACE2, TMPRSS2 and the androgen receptor. PROGRES EN UROLOGIE, 2020, 30: 484–487.